Cross-Market Price Comparison
| Other Listed Market | To be extracted |
|---|---|
| Other Market Stock Code | To be extracted |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Beone Medicines |
|---|---|
| Stock Code | 06160 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家商業階段的生物技術公司,專注於開發及商業化用於治療癌症的創新型分子靶向及腫瘤免疫治療藥物。我們內部開發的主要候選藥物處於臨床後期階段,並於中國銷售三種授權許可藥物。 |
| Listing Date | 2018-08-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市昌平區中關村生命科學園科學園路30號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.beigene.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | Yes (NASDAQ) |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 108.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 100 shares |
| Entry Threshold | To be extracted |
| Par Value | RMB 0.0001 / shares |
| Offer Period | 2018-07-30 to 2018-08-02 |
| Global Offering Shares | 65,600,000 shares |
| HK Public Offer Shares (Initial) | 5,904,000 shares (9.0%) |
| Public Offer Lots (Initial) | 59,040lots (Pool A29,520lots,Pool B29,520lots) |
| International Placing Shares (Initial) | 59,696,000 shares (91.0%) |
| Offer Ratio | ~9.0% |
| Total Shares Post-IPO | 767,163,184 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 31.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 7,084,800,000 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 292.18B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 79,017,807,952 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 截至2017年12月31日止年度,BeiGene, Ltd.應佔虧損淨額約96.0百萬美元。 |
| Period-End Cash Balance | 約239.6百萬美元(2017年12月31日現金及現金等價物) |
| Listing Expenses | ~HK$ 280,300,000 |
| Listing Expenses / Funds Raised | ~3.96% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
USD
Income Statement
| Item | 2016 | 2017 | 2018-03 |
|---|---|---|---|
| Revenue | 1,070 | 254,694 | 32,544 |
| Cost of sales | 0 | -98,033 | -4,550 |
| Other income and gains, net | 443 | 21,077 | 814 |
| Operating profit | -117,060 | -82,150 | -110,809 |
| Net finance costs | 383 | -4,108 | 1,552 |
| Profit before tax | -119,163 | -65,137 | -108,528 |
| Income tax expense | -54 | -30,730 | -3,412 |
| Profit for the year | -119,217 | -95,867 | -105,116 |
| Profit attributable to owners | -119,217 | -96,034 | -104,596 |
Balance Sheet
| Item | 2016 | 2017 | 2018-03 |
|---|---|---|---|
| Cash and cash equivalents | 87,514 | 239,602 | 490,634 |
| Trade and bills receivables | 0 | 29,428 | 23,485 |
| Inventories | 0 | 10,930 | 7,498 |
| Total current assets | 374,399 | 929,804 | 1,585,702 |
| Total assets | 405,813 | 1,034,198 | 1,708,927 |
| Total current liabilities | 35,058 | 149,988 | 141,896 |
| Total liabilities | 52,906 | 352,258 | 350,205 |
| Total equity | 352,907 | 681,940 | 1,358,722 |
| Equity attributable to owners | 352,907 | 667,143 | 1,344,381 |
| Interest-bearing borrowings | 17,284 | 164,715 | 173,681 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018-03 |
|---|---|---|---|
| Net cash from operating activities | -89,513 | 12,752 | -104,501 |
| Net cash from investing activities | -221,848 | -356,319 | -394,352 |
| Net cash from financing activities | 380,902 | 490,356 | 763,901 |
| Net increase in cash | 69,645 | 152,088 | 268,492 |
| Purchase of PP&E | -23,502 | -46,374 | -9,696 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 107.0 |
|---|---|
| First Day Open | HK$ 108.0 |
| First Day Change | -0.93% |
| First Day Volume | 6857700.0 |
| First Day Turnover | 727956000.0 |
| Use of Proceeds | 1、75%(或4,857.4百萬港元)用于zanubrutinib、tislelizumab及pamiparib:
2、15%或(或971.5百萬港元)將用于透過內部研究及外部授權及業務發展合作,為我們在癌癥及其他潛在治療領域的產品組合持續擴充提供資金;
3、10%或(或647.6百萬港元)用作營運資金、拓展內部能力及一般企業目的。 |
Underwriting Syndicate
Overall Coordinators (4)
Joint Bookrunners (7)
Joint Lead Managers (8)
Morgan Stanley Asia Limited CE AAD291
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Credit Suisse (Hong Kong) Limited CE AAO017
中信里昂证券有限公司 CE AAB893
中国国际金融香港证券有限公司 CE AEN894
Deutsche Bank AG, Hong Kong Branch CE AAK077
UBS Securities Hong Kong Limited CE BIN466
China Renaissance Securities (Hong Kong) Limited CE AZX839
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Ally Bridge LB Healthcare Master Fund Limited | 196,225,200 HKD | — | 2.77% | — | 6 months | 2019-02-08 |
| 2 | Baker Brothers Life Sciences, L.P. | 627,922,800 HKD | — | 8.86% | — | 6 months | 2019-02-08 |
| 3 | GIC Private Limited | 784,900,800 HKD | — | 11.08% | — | 6 months | 2019-02-08 |
| 4 | Hillhouse Funds | 585,792,000 HKD | — | 8.27% | — | 6 months | 2019-02-08 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 歐雷強 | — |
| Company Secretary | 周慶齡 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Julian C. Baker及Felix J. Baker各持有約21.07%;Baker Bros. Advisors (GP) LLC及Baker Bros. Advisors LP各持有約21.06%;Baker Brothers Life Sciences, L.P.持有18.93%;歐雷強持有10.84%;Hillhouse Capital Management Ltd.持有9.98%。 |
|---|




